Skip to content

Efficacy of transcutaneous electrical acupoint stimulation(TEAS) combined with warm acupuncture for breast cancer related upper limb lymphedem

Efficacy of transcutaneous electrical acupoint stimulation(TEAS) combined with warm acupuncture for breast cancer related upper limb lymphedem

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200006370
Enrollment
Unknown
Registered
2022-07-21
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Complete detumescence therapy (CDT) group:Nil
TEAS combined with warm acupuncture therapies group:Nil

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria of lymphedema, grade I and above edema occurred; (2) Age 18-70 years old; (3) Have the ability of daily living, Karnofsky function score > 70, and can cooperate independently to complete all treatments; (4) No severe diseases such as gravity center, liver, brain, and kidney, and no severe mental diseases.

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the above requirements; (2) Pregnant women, or complicated with other serious diseases, advanced cachexia, etc.; (3) Limb edema caused by other diseases; (4) Those who do not cooperate with the treatment or are participating in other acupuncture or drug clinical trials.

Design outcomes

Primary

MeasureTime frame
Evaluation of the swelling feeling of the affected limb: visual analog scale(VAS) score was adopted;Measuring the arm circumference of the affected limb;

Countries

China

Contacts

Public ContactLu Chao

Department of the Traditional Chinese Medicine ,Zhejiang Cancer Hospital

1069103617@qq.com15869128904

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026